secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0000950170-25-088700
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA alignment opens third dosing cohort for Perspective's 212Pb-VMT-α-NET NET trial at 6 mCi (20% higher)
--------------------------------------------------------------------------------

- FDA opened Cohort 3 at 6 mCi (20% higher than Cohort 2) per dose for patients weighing >60 kg.
- No DLTs observed among 42 patients treated; no grade ≥4 AEs; anti-tumor activity in 4 of 7 Cohort 2 DLT-evaluable patients.
- Dosimetry sub-study using [203Pb]VMT-α-NET presented at SNMMI 2025 shows feasibility and tolerable absorbed doses.
- Company on track to submit further clinical updates in 2H 2025, including longer safety and anti-tumor activity data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017025088700/0000950170-25-088700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017025088700/catx-20250621.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-088700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer